Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00479323 · ClinicalTrials.gov registry record · Phase 1

Pneumococcal Reference Standard

A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Completed
Registry status
Phase 1
Development phase
250
Enrollment target

NCT00479323: Completed Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

NCT00479323 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 250 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (317% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00479323, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

COMPLETED
Registry status
Phase 1
Development phase
250 participants
Enrollment target

Study Summary

Serum 89 SF is a supply of serum that was collected from people who were vaccinated with the pneumococcal vaccine in the late 1980s. The supply of this serum is running low. The purpose of this study is to give the pneumococcal vaccine to healthy volunteers and take serum blood samples in order to increase the reference serum supply. Study participants will include 250 healthy men and women, ages 18-45. Study procedures will include a physical exam, interviews, blood samples and blood testing. All volunteers will receive the pneumococcal vaccine in the deltoid muscle of the arm. Participants will be involved in the study for approximately 17 weeks.

Interventions

  • BIOLOGICAL Pneumovax 23

Trial Details

FieldValue
Enrollment Target 250 participants
Start Date 2007-06
Est. Completion 2008-08
Phase Phase 1

What the finished NCT00479323 record still lists

NCT00479323 is an interventional study that assigns participants to a tested intervention. The registered 250 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (317% higher).

The record links to 0 conditions, and to 1 intervention - of which Pneumovax 23 is the first listed.

NCT00479323 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00479323 about?

NCT00479323 is a clinical study titled "Pneumococcal Reference Standard". Serum 89 SF is a supply of serum that was collected from people who were vaccinated with the pneumococcal vaccine in the late 1980s. The supply of this serum is running low. The purpose of this study is to give the pneumococcal vaccine to healthy volunteers and take serum blood samples in order to i...

What is the current status of trial NCT00479323?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 250 participants. The study started on 2007-06. Estimated completion is 2008-08.

What interventions are being tested in trial NCT00479323?

The interventions under investigation include: Pneumovax 23 (BIOLOGICAL).

Who is sponsoring clinical trial NCT00479323?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00479323's enrollment target sits among peer trials

250 173rd of 2000 higher than 1,816 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00483249 · 250 participants · NA

    Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm

  • NCT00777712 · 250 participants

    Mechanisms Underlying Impaired Diabetic Wound Healing

  • NCT01451502 · 250 participants · NA

    Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units

  • NCT01771718 · 250 participants

    Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00479323, the US trial registry maintained by the National Library of Medicine. NCT00479323 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.